# RGS22

## Overview
RGS22 is a gene that encodes the protein regulator of G protein signaling 22, which is a member of the RGS protein family. This family is known for its role in modulating G protein-coupled receptor (GPCR) signaling pathways. The RGS22 protein is characterized by the presence of multiple RGS-boxes and is predominantly expressed in the testis. It functions as a GTPase-activating protein (GAP), accelerating the hydrolysis of GTP on Gα subunits, thereby terminating GPCR signaling. RGS22 is involved in various cellular processes, including the regulation of cell migration and invasion, particularly in the context of cancer. It interacts with specific G protein subunits, such as GNA12 and GNA13, and is implicated in the modulation of the actin cytoskeleton. The gene's expression and mutations have been associated with tumor progression and prognosis in several cancers, highlighting its potential as a therapeutic target (Cao2022Suppressive; HU2015RGS22; Yang2024Unraveling).

## Structure
RGS22 is a protein that contains multiple RGS-boxes and is specific to the testis. It is part of the RGS protein family, which is involved in regulating G protein signaling pathways. The protein is noted to have up to three putative Regulator of G Protein Signaling Homology (RH) domains, characterized by a signature of core hydrophobic residues (Tesmer2009Chapter; Siderovski2005The). These RH domains are versatile folds that mediate protein-protein interactions, often involving heterotrimeric G protein signaling pathways (Tesmer2009Chapter).

The RH domain of RGS proteins, including RGS22, is a bundle of nine helices forming a nonglobular structure with two lobes: the 'bundle subdomain' and the 'terminal subdomain' (Tesmer2009Chapter). This structure allows the RH domain to interact with G protein subunits and other proteins simultaneously (Tesmer2009Chapter). The RH domain is crucial for the GTPase-activating protein (GAP) activity of RGS proteins, which accelerates GTP hydrolysis on Gα subunits, thereby terminating signaling through G-protein-coupled receptors (GPCRs) (Li2023RGS).

RGS22 is also associated with various G proteins in pull-down assays, indicating its role in protein-protein interactions (Tesmer2009Chapter). The potential for developing small molecule inhibitors targeting RH domains to disrupt their interactions with other proteins has been noted, highlighting the significance of these domains in therapeutic applications (Tesmer2009Chapter).

## Clinical Significance
RGS22 has been implicated in various cancers, with its expression and mutations affecting tumor progression and patient prognosis. In breast cancer, RGS22 is considered a tumor suppressor gene candidate, with mutations present in 6% of samples. These mutations are significantly correlated with clinical outcomes, suggesting that altered RGS22 expression is associated with worse relapse-free survival (Pongor2015A). In gastric cancer, RGS22 shows a higher mutational frequency of 11% and is linked to poor prognosis. It is part of a prognostic risk model indicating that high-risk patients have poorer clinical outcomes, with pathways related to tumor microenvironment remodeling being enriched in high-risk subgroups (Yang2024Unraveling).

In pancreatic ductal adenocarcinoma (PDAC), RGS22 acts as a tumor suppressor. Its overexpression suppresses cell proliferation, migration, and invasion, while knockdown enhances these processes. RGS22 is regulated by the transcription factor YY1, which enhances its expression and contributes to its suppressive effects on PDAC cells (Cao2022Suppressive). RGS22 also inhibits pancreatic adenocarcinoma cell migration through interactions with the G12/13 α subunit and F-actin pathway, suggesting its role in reducing metastasis (HU2015RGS22).

## Interactions
RGS22 interacts specifically with the G12/13 α subunits, GNA12 and GNA13, in pancreatic adenocarcinoma cells. These interactions are crucial for its role in inhibiting cell migration and invasion. RGS22 binds to these Gα subunits under GDP-ALF4- conditions, indicating a specific binding affinity, but does not interact with GNAq/11 (HU2015RGS22). The interaction with GNA12 and GNA13 is significant in modulating the actin cytoskeleton, as RGS22 overexpression delays lysophosphatidic acid (LPA)-induced F-actin formation and cell deformation, thereby inhibiting cell migration (HU2015RGS22).

RGS22 also interacts with the transcription factor Yin Yang-1 (YY1), which regulates its expression. YY1 binds directly to the promoter region of RGS22, enhancing its expression. This interaction is significant in the context of pancreatic ductal adenocarcinoma, where YY1-mediated regulation of RGS22 suppresses tumor proliferation, migration, and invasion (Cao2022Suppressive). These interactions highlight the role of RGS22 in cellular signaling pathways and its potential as a therapeutic target in cancer treatment.


## References


[1. (Siderovski2005The) David P. Siderovski and Francis S. Willard. The gaps, gefs, and gdis of heterotrimeric g-protein alpha subunits. International Journal of Biological Sciences, pages 51–66, 2005. URL: http://dx.doi.org/10.7150/ijbs.1.51, doi:10.7150/ijbs.1.51. This article has 572 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.1.51)

[2. (Li2023RGS) Lin Li, Qiang Xu, and Chao Tang. Rgs proteins and their roles in cancer: friend or foe? Cancer Cell International, April 2023. URL: http://dx.doi.org/10.1186/s12935-023-02932-8, doi:10.1186/s12935-023-02932-8. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-023-02932-8)

[3. (Yang2024Unraveling) Yalan Yang, Siyuan Xing, Xi Luo, Lulu Guan, Yao Lu, Yiting Wang, and Feng Wang. Unraveling the prognostic significance of rgs gene family in gastric cancer and the potential implication of rgs4 in regulating tumor-infiltrating fibroblast. Frontiers in Molecular Biosciences, April 2024. URL: http://dx.doi.org/10.3389/fmolb.2024.1158852, doi:10.3389/fmolb.2024.1158852. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2024.1158852)

[4. (Cao2022Suppressive) Shou-Ji Cao, Wan-Li Ge, Ling-Dong Meng, Qun Chen, Yi Miao, Kui-Rong Jiang, and Jing-Jing Zhang. Suppressive effect of yy1‑mediated rgs22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. Oncology Letters, November 2022. URL: http://dx.doi.org/10.3892/ol.2022.13577, doi:10.3892/ol.2022.13577. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2022.13577)

[5. (Pongor2015A) Lőrinc Pongor, Máté Kormos, Christos Hatzis, Lajos Pusztai, András Szabó, and Balázs Győrffy. A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Medicine, October 2015. URL: http://dx.doi.org/10.1186/s13073-015-0228-1, doi:10.1186/s13073-015-0228-1. This article has 62 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13073-015-0228-1)

[6. (Tesmer2009Chapter) John J.G. Tesmer. Chapter 4 Structure and Function of Regulator of G Protein Signaling Homology Domains, pages 75–113. Elsevier, 2009. URL: http://dx.doi.org/10.1016/S1877-1173(09)86004-3, doi:10.1016/s1877-1173(09)86004-3. This article has 77 citations.](https://doi.org/10.1016/S1877-1173(09)86004-3)

[7. (HU2015RGS22) YANQIU HU, JUN XING, LING CHEN, YING ZHENG, and ZUOMIN ZHOU. Rgs22 inhibits pancreatic adenocarcinoma cell migration through the g12/13 α subunit/f-actin pathway. Oncology Reports, 34(5):2507–2514, August 2015. URL: http://dx.doi.org/10.3892/or.2015.4209, doi:10.3892/or.2015.4209. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2015.4209)